A phase i open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 4, 2011, Pages 751-764

  Tolcher, Anthony W ^a   Appleman, Leonard J ^b   Shapiro, Geoffrey I ^c,d   Mita, Alain C ^e   Cihon, Frank ^f   Mazzu, Arthur ^g   Sundaresan, Pavur R ^g  

^a South Texas Accelerated Research Therapeutics   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e CTRC Institute for Drug Development   (United States)

^f Bayer Healthcare Pharmaceuticals Inc   (United States)

^g Bayer HealthCare Pharmaceuticals Inc   (United States)

Author keywords

Cardiovascular adverse event (CAE); Cardiovascular profile; Hypertension; Left ventricular ejection fraction (LVEF); QT QTc interval; Sorafenib

Indexed keywords

BAY 43 9007; BAY 67 3472; BAY 68 7769; DRUG METABOLITE; MOXIFLOXACIN; PLACEBO; SORAFENIB; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE MEASUREMENT; BRAIN ISCHEMIA; CANCER OF UNKNOWN PRIMARY SITE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOLTER MONITORING; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY CARCINOMA; LIMB PAIN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MESOTHELIOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OSTEOSARCOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROSTATE CANCER; QT INTERVAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; SYSTOLIC BLOOD PRESSURE; THYROID PAPILLARY CARCINOMA; TIME TO MAXIMUM PLASMA CONCENTRATION;

AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BENZENESULFONATES; BLOOD PRESSURE; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PYRIDINES; VENTRICULAR FUNCTION, LEFT;

EID: 79954431917     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1372-3     Document Type: Article

References (46)

1. AY Khakoo CM Kassiotis N Tannir, et al. 2008 Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor Cancer 112 2500 2508 18386829 10.1002/cncr.23460 1:CAS:528:DC%2BD1cXnsFGju78%3D
2. R Kerkela L Grazette R Yacobi, et al. 2006 Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat Med 12 908 916 16862153 10.1038/nm1446 (Pubitemid 44175142)
3. JP Machiels N Bletard P Pirenne, et al. 2008 Acute cardiac failure after sunitinib Ann Oncol 19 597 599 18272908 10.1093/annonc/mdn019 (Pubitemid 351325687)
4. M Schmidinger CC Zielinski UM Vogl, et al. 2008 Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 26 5204 5212 18838713 10.1200/JCO.2007.15.6331
5. TF Chu MA Rupnick R Kerkela, et al. 2007 Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 2011 2019 18083403 10.1016/S0140-6736(07)61865-0 1:CAS:528:DC%2BD2sXhsVent7bN (Pubitemid 350236338)
6. CF Wu WP Chuang AH Li CH Hsiao 2009 Cardiac magnetic resonance imaging in sunitinib malate-related cardiomyopathy: no late gadolinium enhancement J Chin Med Assoc 72 323 327 19541568 10.1016/S1726-4901(09)70379-X
7. ML Telli RM Witteles GA Fisher S Srinivas 2008 Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate Ann Oncol 19 1613 1618 18436521 10.1093/annonc/mdn168 1:STN:280:DC%2BD1crivFWmsw%3D%3D
8. M Schmidinger A Bojic UM Vogl W Lamm CC Zielinski 2009 Management of cardiac adverse events occurring with sunitinib treatment Anticancer Res 29 1627 1629 19443377 1:CAS:528:DC%2BD1MXos1Wnt7g%3D
9. G Di Lorenzo R Autorino G Bruni, et al. 2009 Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis Ann Oncol 20 1535 1542 19474115 10.1093/annonc/mdp025 1:STN:280:DC%2BD1MrnsVGhuw%3D%3D
10. Hutson TE, Figlin RA, Tabesh M, Niculescu L, Motzer RJ (2010) Sunitinib-associated changes in left ventricular ejection fraction (LVEF) in treatment-naïve patients (pts) with metastatic renal cell carcinoma (mRCC). Am Soc Clin Oncol (Genitourinary cancers symposium Abstract 370)
11. SM Wilhelm C Carter L Tang, et al. 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099 7109 15466206 10.1158/0008-5472.CAN-04-1443 1:CAS:528: DC%2BD2cXotFalsbk%3D (Pubitemid 39331023)
12. Y Izumiya I Shiojima K Sato, et al. 2006 Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload Hypertension 47 887 893 16567591 10.1161/01.HYP.0000215207.54689.31 1:CAS:528:DC%2BD28XjsVeksrs%3D (Pubitemid 44297560)
13. MH Chen R Kerkela T Force 2008 Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics Circulation 118 84 95 18591451 10.1161/CIRCULATIONAHA.108.776831
14. BB Hasinoff D Patel KA O'Hara 2008 Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib Mol Pharmacol 74 1722 1728 18815214 10.1124/mol.108.050104 1:CAS:528: DC%2BD1cXhsVGls7rF
15. Y Will JA Dykens S Nadanaciva, et al. 2008 Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells Toxicol Sci 106 153 161 18664550 10.1093/toxsci/kfn157 1:CAS:528:DC%2BD1cXht1emtb7I
16. T Force DS Krause RA Van Etten 2007 Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition Nat Rev Cancer 7 332 344 17457301 10.1038/nrc2106 1:CAS:528:DC%2BD2sXksFSiu7w%3D (Pubitemid 46652481)
17. B Escudier T Eisen WM Stadler, et al. 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 17215530 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D (Pubitemid 46089673)
18. JM Llovet S Ricci V Mazzaferro, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 18650514 10.1056/NEJMoa0708857 1:CAS:528:DC%2BD1cXovFWjsL8%3D
19. B Escudier T Eisen WM Stadler, et al. 2009 Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 3312 3318 19451442 10.1200/JCO.2008.19.5511 1:CAS:528:DC%2BD1MXpvFejt7w%3D
20. Snow H, Brueckner A, Gelder M, Voliotis D, Kelley S (2008) Sorafenib is not associated with a high incidence of cardiovascular events in many tumor types. Ann Oncol 19:179
21. N Sarapa J Morganroth J-P Couderc, et al. 2004 Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods Ann Noninvasive Electrocardiol 1 48 57 10.1111/j.1542-474X.2004.91546.x (Pubitemid 38230430)
22. JL Demolis D Kubitza L Tenneze C Funck-Brentano 2000 Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects Clin Pharmacol Ther 68 658 666 11180026 10.1067/mcp.2000.111482 1:CAS:528:DC%2BD3MXht1Sjsbw%3D (Pubitemid 32059992)
23. JW Clark JP Eder D Ryan C Lathia H-J Lenz 2005 Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006 in patients with advanced, refractory solid tumors Clin Cancer Res 11 5472 5480 16061863 10.1158/1078-0432.CCR-04-2658 1:CAS:528:DC%2BD2MXmvFSmtbY%3D (Pubitemid 41060823)
24. DJ Lenihan 2008 Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork? J Clin Oncol 26 5154 5155 18838702 10.1200/JCO.2008.18.5439
25. M Recanatini E Poluzzi M Masetti A Cavalli PF De 2005 QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development Med Res Rev 25 133 166 15389727 10.1002/med.20019 1:CAS:528:DC%2BD2MXitlWhs7Y%3D (Pubitemid 40299844)
26. ICH Harmonised Tripartite Guideline (2005) The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic. Drugs E14
27. D Kubitza W Mueck M Becka 2008 Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation Drug Saf 31 67 77 18095747 10.2165/00002018-200831010-00006 1:CAS:528:DC%2BD1cXisFCitL4%3D
28. CL Bello M Mulay X Huang, et al. 2009 Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic-pharmacodynamic evaluation of sunitinib Clin Cancer Res 15 7045 7052 19903787 10.1158/1078-0432.CCR-09-1521 1:CAS:528:DC%2BD1MXhtl2ktLbI
29. S Wu JJ Chen A Kudelka J Lu X Zhu 2008 Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis Lancet Oncol 9 117 123 18221915 10.1016/S1470-2045(08)70003-2 1:CAS:528:DC%2BD1cXhsVOnu7k%3D
30. X Zhu K Stergiopoulos S Wu 2009 Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis Acta Oncol 48 9 17 18752081 10.1080/02841860802314720 1:CAS:528:DC%2BD1cXhsFagtbjI
31. X Zhu S Wu WL Dahut CR Parikh 2007 Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis Am J Kidney Dis 49 186 193 17261421 10.1053/j.ajkd.2006.11.039 1:CAS:528:DC%2BD2sXis1Kgu78%3D (Pubitemid 46178407)
32. V Ranpura B Pulipati D Chu X Zhu S Wu 2010 Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis Am J Hypertens 23 460 468 20186127 10.1038/ajh.2010.25 1:CAS:528:DC%2BC3cXkvFehsb4%3D
33. BI Rini JH Schiller J Fruehauf, et al. 2008 Association of diastolic blood pressure (dBP) >90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736) J Clin Oncol 26 3543 10.1200/JCO.2007.15.0375
34. SE Dahlberg AB Sandler JR Brahmer JH Schiller DH Johnson 2010 Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599 J Clin Oncol 28 949 954 20085937 10.1200/JCO.2009.25. 4482 1:CAS:528:DC%2BC3cXktF2ltr8%3D
35. Rini BI, Cohen DP, Lu D et al. (2010) Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Am Soc Clin Oncol (Genitourinary cancers symposium Abstract 312)
36. O Rixe J Dutcher R Motzer, et al. 2009 Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC) J Clin Oncol 27 5045
37. M Scartozzi E Galizia S Chiorrini, et al. 2009 Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab Ann Oncol 20 227 230 18842611 10.1093/annonc/mdn637 1:STN:280:DC%2BD1M7jtlWltg%3D%3D
38. ML Maitland K Moshier J Imperial, et al. 2006 Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway J Clin Oncol 24 2035 10.1200/JCO.2005.05.2282 (Pubitemid 46630687)
39. H Izzedine S Ederhy F Goldwasser, et al. 2009 Management of hypertension in angiogenesis inhibitor-treated patients Ann Oncol 20 807 815 19150949 10.1093/annonc/mdn713 1:STN:280:DC%2BD1MzgvVyhsg%3D%3D
40. D Strumberg H Richly RA Hilger, et al. 2005 Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J Clin Oncol 23 965 972 15613696 10.1200/JCO.2005.06.124 1:CAS:528:DC%2BD2MXit1Ggu7c%3D (Pubitemid 46202316)
41. D Strumberg JW Clark A Awada, et al. 2007 Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors Oncologist 12 426 437 17470685 10.1634/theoncologist.12-4-426 1:CAS:528:DC%2BD2sXmtlSitrs%3D (Pubitemid 46698720)
42. WJ van Heeckeren S Bhakta J Ortiz, et al. 2006 Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J Clin Oncol 24 1485 1488 16574996 10.1200/JCO.2005.04.8801 (Pubitemid 46638767)
43. R Altena PJ Perik DJ van Veldhuisen EG de Vries JA Gietema 2009 Cardiovascular toxicity caused by cancer treatment: strategies for early detection Lancet Oncol 10 391 399 19341970 10.1016/S1470-2045(09)70042-7 1:CAS:528:DC%2BD1MXjslOltrk%3D
44. MK Wong A Jarkowski 2009 Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature Pharmacotherapy 29 473 478 19323623 10.1592/phco.29.4.473 1:CAS:528:DC%2BD1MXhtVGisbfI
45. M Mego M Reckova J Obertova, et al. 2007 Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma Ann Oncol 18 1906 1907 17993633 10.1093/annonc/mdm489 1:STN:280: DC%2BD2snntV2nsQ%3D%3D (Pubitemid 350111579)
46. P Kamada AZ Dudek 2010 Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review Cancer Invest 28 501 504 20014944 10.3109/07357900903476794 1:CAS:528:DC%2BC3cXlslCksrw%3D